A clinical study in China for LP-003 in food allergy
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs LP-001 Longbio Pharma (Primary)
- Indications Food hypersensitivity
- Focus Adverse reactions
- 25 Nov 2024 According to a LongBio Pharma media release, company announced that the National Medical Products Administration (NMPA, China) has approved the Investigational New Drug (IND) application for LP-003 for the treatment of food allergy.
- 02 Oct 2024 New trial record
- 24 Sep 2024 According to Longbio Pharma media release, US FDA IND filing food allergy is currently in preparation, and will be submitted later this year.